To assess early hypertensive induced target organ damage using Magnetic Resonance Imaging (MRI) technology. To relate microalbuminuria and low grade systemic inflammation to cardiac, cerebral and aortic target organ damage. Emphasis will be on young…
ID
Source
Brief title
Condition
- Heart failures
- Central nervous system vascular disorders
- Vascular hypertensive disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Manifestations of early end organ damage in patients with hypertension (i.e.
the underneath mentioned MRI outcomes will be used to compare these between
earlier mentioned hypertension subgroups):
Heart:
- Left Ventricular Function, Ejection Fraction, Volume and Mass
- Delayed Contast Enhancement (DCE) to extent transmural left ventricular scar
tissue
Aorta:
- Aortic wall compliance by distensibility and Pulse-wave velocity (PWV)
Brain:
- Precense and size of white matter lesions;
- Presence and size of lacunar and cortical infarctions;
- Brain atrophy and gray/white matter volumes;
- Integrity of white matter fibers;
- Prevalence of microbleeds.
Secondary outcome
The severity of early cardiac, cerebral and aortic target organ damage as
assessed by 3 Tesla MRI, leading to more appropriate risk stratification for
cardiovascular diseases in patients with hypertension. In our study we will
assess early hypertensive induced target organ damage using Magnetic Resonance
Imaging (MRI) technology with special emphasis on young patients and therapy
resistant patients. Microalbuminuria and low grade systemic inflammation are
expected to adversely affect the severity of target organ damage.
Background summary
Hypertension causes target organ damage. It results in stroke, heart and renal
failure in many but not all patients. Early recognition of patients developing
organ damage may result in optimal early treatment in those most likely to
suffer from the deleterious consequences of hypertension. Recently, MRI has
been established as a more accurate tool for assessment of organ damage in the
heart, the aorta and the brain.
Study objective
To assess early hypertensive induced target organ damage using Magnetic
Resonance Imaging (MRI) technology. To relate microalbuminuria and low grade
systemic inflammation to cardiac, cerebral and aortic target organ damage.
Emphasis will be on young patients and patients with therapy resistant
hypertension.
Study design
This is a cross-sectional observational study with a case control design.
Consenting patients referred to the Leiden University Medical Center (LUMC)
hypertension outpatient clinic that fulfill the criteria will have 3 Tesla (T)
MRI assessment of brain, heart and aorta. The 3T MRI assessments will be
performed using well established techniques currently available at the
department of Radiology at the LUMC. Studies will be performed in two to three
years.
Study burden and risks
Duration time:
MRI-assessment will take 2 hours in total, of which 90 minutes in the
MRI-scanmachine.
No radiation doses in MRI.
Patients with hypertension will get an intravenous contrast medium once, i.e.
gadolinium. Only 1% of individuals receiving gadolinium develop contrast
allergy.
Albinusdreef 2, PO Box 9600
2300 RC Leiden
Nederland
Albinusdreef 2, PO Box 9600
2300 RC Leiden
Nederland
Listed location countries
Age
Inclusion criteria
- Age >= 18 years
- Patients with proven hypertension (i.e. blood pressure of > 140/90mmHg on repeated examination according to the criteria of the European Society of Hypertension).
Exclusion criteria
- Routine MRI-contraindications (e.g. instable metal implants, pacemaker/ICD, vascular clips, atrial fibrillation or sustained ventricular tachycardia and claustrophobia).
- Pregnancy
- Renal insufficiency as defined by an MDRD < 30 ml/min/1.73m2
- Gadolinium contrast allergy (no contrast)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL19265.058.07 |